Hospital readmission and mortality in chinese patients with heart failure stratified by ejection fraction levels after treatment with sacubitril/valsartan

被引：0
|
作者：
Ye, X. [1 ]
Chan, E. S. Y. [2 ]
Man, K. K. C. [2 ]
Wong, C. K. [3 ]
Tse, H. F. [3 ]
Chan, E. W. [1 ]
机构：
[1] Univ Hong Kong, Dept Pharmacol & Pharm, Ctr Safe Medicat Practice & Res, Hong Kong, Peoples R China
[2] UCL, Sch Pharm, London, England
[3] Univ Hong Kong, Sch Clin Med, LKS Fac Med, Dept Med, Hong Kong, Peoples R China
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：91 / 92
页数：2
相关论文
共 50 条
  • [1] Sacubitril/valsartan as a Treatment for Resistant Hypertension in Patients With Heart Failure and Preserved Ejection Fraction
    Jhund, Pardeep S.
    Alice, M.
    Pfeffer, Marc A.
    Zannad, Faiez
    Lefkowitz, Martin P.
    Shi, Victor
    Vardeny, Orly
    Solomon, Scott
    McMurray, John J.
    CIRCULATION, 2020, 142
  • [2] Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
    Dewan, Pooja
    Docherty, Kieran F.
    McMurray, John J., V
    KOREAN CIRCULATION JOURNAL, 2019, 49 (06) : 469 - 484
  • [3] Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
    Butt, Jawad H.
    Dewan, Pooja
    Jhund, Pardeep S.
    Anand, Inder S.
    Atar, Dan
    Ge, Junbo
    Desai, Akshay S.
    Echeverria, Luis E.
    Kober, Lars
    Lam, Carolyn S. P.
    Maggioni, Aldo P.
    Martinez, Felipe
    Packer, Milton
    Rouleau, Jean L.
    Sim, David
    Van Veldhuisen, Dirk J.
    Vrtovec, Bojan
    Zannad, Faiez
    Zile, Michael R.
    Gong, Jianjian
    Lefkowitz, Martin P.
    Rizkala, Adel R.
    Solomon, Scott D.
    McMurray, John J., V
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (12) : 1130 - 1143
  • [4] Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients
    Iokfai Cheang
    Shi Shi
    Xinyi Lu
    Shengen Liao
    Xu Zhu
    Xi Su
    Qi Lu
    Jing Yuan
    Dachun Xu
    Min Zhang
    Cuilian Dai
    Jingfeng Wang
    Fang Yuan
    Yan Zhao
    Jingmin Zhou
    Xinli Li
    Journal of Cardiovascular Translational Research, 2022, 15 : 1192 - 1202
  • [5] Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients
    Cheang, Iokfai
    Shi, Shi
    Lu, Xinyi
    Liao, Shengen
    Zhu, Xu
    Su, Xi
    Lu, Qi
    Yuan, Jing
    Xu, Dachun
    Zhang, Min
    Dai, Cuilian
    Wang, Jingfeng
    Yuan, Fang
    Zhao, Yan
    Zhou, Jingmin
    Li, Xinli
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2022, 15 (05) : 1192 - 1202
  • [6] ECHOCARDIOGRAPHIC CHANGES AFTER SACUBITRIL/VALSARTAN TREATMENT IN HEART FAILURE OUTPATIENTS WITH REDUCED EJECTION FRACTION
    Gioia, M.
    Albanese, M.
    Parisi, G.
    Lisi, F.
    Amato, L.
    Urso, R.
    Angelini, G.
    Bellino, I.
    Iacoviello, M.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0G) : G152 - G153
  • [7] Echocardiographic changes in elderly patients with heart failure with reduced ejection fraction after sacubitril-valsartan treatment
    Gu, Wei
    Xu, Chuangye
    Li, Zhao
    Li, Zhi-Zhong
    CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2021, 11 (05) : 1093 - 1100
  • [8] Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction
    Raschi, Emanuel
    Diemberger, Igor
    Sabatino, Mario
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    Potena, Luciano
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (03) : 303 - 320
  • [9] Economic evaluation of sacubitril/valsartan for the treatment of heart failure with reduced ejection fraction
    Stafylas, P.
    Farmakis, D.
    Giamouzis, G.
    Hatzikou, M.
    Kourlaba, G.
    Papatsouma, I.
    Maniadakis, N.
    EUROPEAN HEART JOURNAL, 2016, 37 : 730 - 731
  • [10] Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
    Rex C. Liu
    American Journal of Cardiovascular Drugs, 2018, 18 : 473 - 482
12345